Yuichi Sakamori

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda et al. · Cancer Chemotherapy and Pharmacology · 2012 · 282 citations

Cerebrospinal Fluid Concentration, Medicine, Pathology +7

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab

Ichiro Yamauchi, Akihiro Yasoda, Shigemi Matsumoto et al. · PLoS ONE · 2019 · 132 citations · Full text

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo et al. · Journal of Thoracic Oncology · 2010 · 130 citations · Full text

Cerebrospinal Fluid Concentration, Medicine, Metronomic Therapy +8

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji et al. · Scientific Reports · 2017 · 117 citations · Full text

Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

Ryusuke Hatae, Kenji Chamoto, Young Hak Kim et al. · JCI Insight · 2019 · 87 citations · Full text

Immunology, Metabolomic Profiling, Immunotherapy +22